The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Cardiac comorbidities and PTCy-induced toxicity
In this video, Alexandros Spyridonidis, MD, University of Patras, Patras, Greece, comments on an analysis of the Acute Leukemia Working Party (ALWP), which assessed the factors that make patients more vulnerable to post-transplant cyclophosphamide (PTCy)-induced toxicity. Prof. Spyridonidis emphasizes that caution should be taken when considering PTCy use in patients with cardiac comorbidities. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We looked also in our database, in the Acute Leukemia Working Party database, and we looked again at the high CTCI. The high CTCI captures the organ dysfunction for specific organs, especially also cardiac dysfunctions. Nowadays we are using more and more PTCy, post-transplant cyclophosphamide and we know that this may be cardiotoxic and indeed we looked that this high CTCI works very nicely also in these patients that they are receiving PTCy...
We looked also in our database, in the Acute Leukemia Working Party database, and we looked again at the high CTCI. The high CTCI captures the organ dysfunction for specific organs, especially also cardiac dysfunctions. Nowadays we are using more and more PTCy, post-transplant cyclophosphamide and we know that this may be cardiotoxic and indeed we looked that this high CTCI works very nicely also in these patients that they are receiving PTCy. But we have to be aware if we have cardiac comorbidities then you have a much bigger score. So if you have cardiac comorbidities it’s better avoid PTCy or be careful about that because the score that you get with high CTCI is not the same. You have an extra weighted score if you have cardiac comorbidities. So we have to be aware of that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
